



Pharmacotherapy in patients with COPD Position Statement

COPD Working Group - CONFLICT OF INTEREST

Name	CTS affiliation	Disclosure	Updated
Aaron, Shawn	COPD	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Chief, Division of Respiratory Medicine, The Ottawa Hospital, Professor, Division of Respirology, University of Ottawa</p> <p>University: University of Ottawa</p> <p>Hospital: The Ottawa Hospital</p> <p>Research Funding:</p> <p>Peer-reviewed grants: CIHR</p> <p>Consultant/Advisor:</p> <p>Industry advisory board member: Glaxo Smith Kline, Astra Zeneca, Novartis, and Boehringer-Ingelheim</p> <p>Honoraria:</p> <p>Speaker: \$1500 for Astra Zeneca</p> <p>Volunteer/Board or Committee Member:</p> <p>Charitable Organization/Not for profit: The Ontario Lung Association</p>	May 2017
Balter, Meyer	COPD	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: Professor of Medicine</p> <p>University: University of Toronto</p> <p>Hospital: Mount Sinai Hospital</p> <p>Consultant/Advisor:</p> <p>Industry advisory board member: AstraZeneca, Boehringer-Ingelheim, Novartis, TEVA</p> <p>Honoraria:</p> <p>Speaker: AstraZeneca, Boehringer-Ingelheim, Novartis</p> <p>CME/Course development:</p> <p>Development of educational material: AstraZeneca, Boehringer-Ingelheim</p> <p>Volunteer/Board or Committee Member:</p> <p>Charitable Organization/Not for profit: ACCP</p>	March 2017

Name	CTS affiliation	Disclosure	Updated																		
Beauchesne, Marie-France	External expert approved by the CTS Board of Directors	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: University: Faculté de pharmacie, Université de Montréal Hospital: Département de pharmacie, CIUSSS de l’Estrie-CHUS Other: Centre de recherché du CHUS</p> <p>Research Funding: Other: Research projects initiated by the investigator and sponsored by the pharmaceutical industry (note: all protocols have been peer reviewed by the scientific and ethics committee of the CR CHUS).</p> <table border="1" data-bbox="709 440 1833 959"> <thead> <tr> <th>Projet Title</th> <th>Source of Funding</th> <th>Amount</th> </tr> </thead> <tbody> <tr> <td>Validité externe des essais cliniques randomisés contrôlés sur les médicaments inhalés en maladie pulmonaire obstructive chronique et évaluation des préférences et techniques d’inhalation des médicaments inhalés des patients (Étude VERITAS)</td> <td>AstraZeneca</td> <td>34 212,50 \$</td> </tr> <tr> <td>Support for the CIUSSS de l’Estrie-CHUS “RESP” database</td> <td>AstraZeneca</td> <td>15 000\$</td> </tr> <tr> <td>Caractérisation des patients asthmatiques non-contrôlés, ayant une MPOC ou le syndrome de chevauchement de l’asthme et de la MPOC</td> <td>Boehringer-Ingelheim</td> <td>11 290\$</td> </tr> <tr> <td>Projet d’amélioration de la pratique et suivi systématique d’une clientele vulnérable MPOC</td> <td>Novartis</td> <td>10 000\$</td> </tr> <tr> <td>Long-acting anticholinergics (LAAC) in patients with chronic obstructive pulmonary disease (COPD): adherence, persistence, and side effects.</td> <td>Almirall (AstraZeneca)</td> <td>93 870,25 \$</td> </tr> </tbody> </table>	Projet Title	Source of Funding	Amount	Validité externe des essais cliniques randomisés contrôlés sur les médicaments inhalés en maladie pulmonaire obstructive chronique et évaluation des préférences et techniques d’inhalation des médicaments inhalés des patients (Étude VERITAS)	AstraZeneca	34 212,50 \$	Support for the CIUSSS de l’Estrie-CHUS “RESP” database	AstraZeneca	15 000\$	Caractérisation des patients asthmatiques non-contrôlés, ayant une MPOC ou le syndrome de chevauchement de l’asthme et de la MPOC	Boehringer-Ingelheim	11 290\$	Projet d’amélioration de la pratique et suivi systématique d’une clientele vulnérable MPOC	Novartis	10 000\$	Long-acting anticholinergics (LAAC) in patients with chronic obstructive pulmonary disease (COPD): adherence, persistence, and side effects.	Almirall (AstraZeneca)	93 870,25 \$	March 2017
Projet Title	Source of Funding	Amount																			
Validité externe des essais cliniques randomisés contrôlés sur les médicaments inhalés en maladie pulmonaire obstructive chronique et évaluation des préférences et techniques d’inhalation des médicaments inhalés des patients (Étude VERITAS)	AstraZeneca	34 212,50 \$																			
Support for the CIUSSS de l’Estrie-CHUS “RESP” database	AstraZeneca	15 000\$																			
Caractérisation des patients asthmatiques non-contrôlés, ayant une MPOC ou le syndrome de chevauchement de l’asthme et de la MPOC	Boehringer-Ingelheim	11 290\$																			
Projet d’amélioration de la pratique et suivi systématique d’une clientele vulnérable MPOC	Novartis	10 000\$																			
Long-acting anticholinergics (LAAC) in patients with chronic obstructive pulmonary disease (COPD): adherence, persistence, and side effects.	Almirall (AstraZeneca)	93 870,25 \$																			

Name	CTS affiliation	Disclosure	Updated
Beauchesne (con'td)		<p>Honoraria: Speaker: I have received honoraria from the pharmaceutical industry for the following CME in the last year: 2016, Mai 3 - Gestion de la MPOC en Établissement de santé au Québec. Webconférence subventionnée par BI. 2016, Mai 11 - Prise en charge de l'asthme, à l'ère des nouveautés pharmacologiques, Pharmaciens communautaires de Sherbrooke. Conférence subventionnée par AstraZeneca. 2016, Mai 26 - Projet d'amélioration de la pratique auprès des patients MPOC vulnérables. Webconférence subventionnée par Novartis. 2016, Mai 31 - Caractérisation des patients asthmatiques, MPOC et ACOS. Webconférence subventionnée par BI. 2016, Juin 9 - Revue de la pharmacothérapie des médicaments inhalés en CHSLD. Webconférence. Conférence subventionnée par Novartis. 2016, Novembre 22 - Évaluation de l'usage des médicaments respiratoires en MPOC. Bureau-Chef de Novartis, Montréal. 2016, Novembre 24 - Optimisation de l'usage des médicaments pour MPOC en CHSLD, WebConférence pour les hôpitaux de l'Estrie, subventionnée par Novartis. 2016, Décembre 6 - Usage des médicaments pour MPOC en CHSLD, WebConférence pour les hôpitaux de la province, subventionnée par Novartis.</p> <p>CME/Course development: Peer Reviewer: Review of the CME program titled "Changing the conversation. Adding the art of medicine to asthma management" sponsored by AstraZeneca.</p> <p>Other (please specify): Co-holder of the endowment AstraZeneca pharmaceutical Chair.</p>	

Name	CTS affiliation	Disclosure	Updated
Bhutani, Mohit	COPD	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment/employment: University: University of Alberta Hospital: University Hospital Research Funding: CIHR, AIHS Peer-reviewed grants: CIHR, AFHS Industry-sponsored contracts: AZ, BI, GSK, Novartis Consultant/Advisor: Industry advisory board member: AZ, BI, GSK, Novartis Honoraria: Speaker: AZ, BI, GSK, Novartis CME/Course development: AZ, BI, GSK, Novartis</p>	

Name	CTS affiliation	Disclosure	Updated
Bourbeau, Jean	COPD CTS Board of Directors	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: University: Full professor at McGill University Hospital: Respiriologist, Montreal Chest Institute of the Royal Victoria Hospital, of the McGill University Health Centre Other:</p> <ul style="list-style-type: none"> •Director, Centre of Innovative Medicine, The Research Institute of the McGill University Health Centre •Director, COPD clinic and pulmonary rehabilitation, McGill University Health Centre •Member of Scientific Committee Global Initiative for COPD (GOLD) •Member, Pulmonary Rehab Assembly, American Thoracic Society •Pneumologue expert du Comité du Réseau montréalais en maladies chroniques •Member of the COPD committee Canadian Thoracic Society <p>Research Funding: Peer-reviewed grants:</p> <p>CIHR</p> <ul style="list-style-type: none"> •2017/4 - 2020/3 - Principal Applicant - COPD disease categorization using cardiovascular risk and levels of inflammatory mediators: a way to toward more personalized care •2015/3 - 2020/2 - Co-investigator - Development and validation of Canadian health literacy measurement tool for chronic disease management •2015/2 - 2019/12 - Principal Applicant - Better understanding of chronic obstructive pulmonary disease (COPD) and intervention •2014/3 - 2019/2 - Co-investigator - Optimizing physician training in motivational communication (MC) skills for health behavior change •2016/3 - 2019/2 - Co-investigator - Developing Longitudinal Indicators for Population-Scale Monitoring of Health Care Trajectories <p>CRRN</p> <ul style="list-style-type: none"> •2014/4 - 2018/3 - Principal Applicant - Canadian Cohort Obstructive Lung Disease (CanCOLD) <p>Industry GlaxoSmithKline –</p> <ul style="list-style-type: none"> • 2015/2 - 2019/12 - Principal Applicant -Better understanding of chronic obstructive pulmonary disease (COPD) and intervention •2016/12 - 2017/11 - Principal Applicant -Understanding symptoms (dyspnea) in COPD from mild to moderate-severe disease <p>Grifols -</p> <ul style="list-style-type: none"> •2016/12 - 2019/11 - Principal Applicant - A1ATD: Genetic sequencing and COPD characterization in a population-based COPD Cohort 	October 2017

Name	CTS affiliation	Disclosure	Updated
Bourbeau (cont'd)		<p>Aerocrine -</p> <ul style="list-style-type: none"> •2015/7 - 2018/6 - Principal Applicant - FeNO in COPD <p>Consultant/Advisor: Industry advisory board member:</p> <ul style="list-style-type: none"> • Boehringer Ingelheim (National and International) • AstraZeneca (National) • Novartis (National) • GlaxoSmithKline (International) <p>Government Agency: CIHR: Reviewer Other government body or committee: Provincial Ministry of Health: Chronic respiratory disease committee on the Montreal Territory</p> <p>Honoraria: Speaker: McGill University Health Centre, University de Montréal (UDM), Canadian Thoracic Society, CHEST, Many worldwide respiratory societies, Pharma Industry, (Boehringer Ingelheim , Grifols, AstraZeneca, Novartis)</p> <p>CME/Course development: PREP CTS CHEST Development of educational material: Respiplus (Living Well With COPD), Resptrec, RQESR</p> <p>Volunteer/Board or Committee Member: CTS, Respiplus, Réseau en santé respiratoire du FRQS, RQESR, RESPTrec</p> <p>Charitable Organization/Not for profit: Quebec Lung Association, Fondation Québécoise en santé respiratoire</p> <p>As a member of the CTS Board of Directors are you: Related to a provincial or federal government employee or official (please specify): No</p>	
D'Urzo, Anthony	Appointed by the Canadian Family Physicians of Canada	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: University: University of Toronto, Faculty of medicine, Dept of family and Community Medicine. Hospital: Toronto Western Hospital Research Funding: Industry-sponsored contracts: Novartis Canada/ AstraZeneca Canada/ Boehringer Ingelheim (Canada) Consultant/Advisor: Novartis Canada/Global AstraZeneca Canada/ Boehringer Ingelheim (Canada) Industry advisory board member: TEVA Pharmaceuticals Canada, Novartis Canada/Global AstraZeneca Canada/ Boehringer Ingelheim (Canada) Honoraria: Merck Canada, Novartis Canada/Global AstraZeneca Canada/ Boehringer Ingelheim (Canada), TEVA Pharmaceuticals Canada Speaker: Merck Canada, Novartis Canada/Global AstraZeneca Canada/ Boehringer Ingelheim (Canada) CME/Course development: Development of educational material: Novartis Canada</p>	May 2017

Name	CTS affiliation	Disclosure	Updated
Goldstein, Roger	COPD	<p>Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p> <p>Academic appointment(s)/employment: University: Toronto Hospital: West Park Consultant/Advisor: Provincial Ministry of Health: Yes</p>	April 2017
Hernandez, Paul	COPD CRGC	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: University: Dalhousie University Hospital: QEII Health Sciences Centre, Nova Scotia Health Authority Research Funding: Peer-reviewed grants: CIHR Industry-sponsored contracts: Boehringer Ingelheim; Prometic; Grifols; CSL Behring Consultant/Advisor: Industry advisory board member: Actelion; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Grifols; Merck; Novartis; Roche Honoraria: Speaker: AstraZeneca; Bayer; Boehringer Ingelheim; Grifols; Merck; Novartis; Roche CME/Course development: Boehringer Ingelheim; CTS; MD Briefcase; Development of educational material: Peer Reviewer: Dalhousie University Academic Detailing Service Volunteer/Board or Committee Member: Charitable Organization/Not for profit: Lung Association of Nova Scotia</p>	March 2017
Kaplan, Alan	COPD Pediatric Assembly Appointed by the Canadian Family Physicians of Canada	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: University: Toronto Consultant/Advisor: Industry advisory board member: Boehringer, Astra, GSK, Meda, Pfizer, Novartis, Purdue, Teva Government Agency: Health Canada: Section of Allergy and Respiratory Therapeutics Public Health Agency of Canada: Respiratory Surveillance Honoraria: Speaker: Boehringer, Astra, GSK, Merck, Pfizer, Purdue, NovartisJohnson and Johnson,</p>	March 2017

Name	CTS affiliation	Disclosure	Updated
Maltais, François	COPD HMV	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: University: Professor, Université Laval Hospital: Institut Universitaire de cardiologie et de pneumologie de Québec Research Funding: Peer-reviewed grants: CIHR, CRRN Industry-sponsored contracts: Novartis, Griffols, Boehringer Ingelheim, AstraZeneca Consultant/Advisor: Industry advisory board member: Novartis Government Agencies: Drug approval committee: INESSS (ad hoc committee in 2015) Honoraria: Speaker: Boehringer Ingelheim, Novartis, Griffols Volunteer/Board or Committee Member: Charitable Organization/Not for profit: FRQS (scientific review committee)</p>	
Marciniuk, Darcy	COPD CTS Long-Term Planning Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment/employment: University: Saskatchewan Hospital: Royal University Hospital Research Funding: Peer-reviewed grants: CIHR, Canada Health Infoway, Lung Assoc of Saskatchewan Health Research Foundation Industry-sponsored contracts: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Schering-Plough Other: Lung Health Institute Consultant/Advisor: Government Agency: Canadian Foundation for Healthcare Improvement, Health Canada, Lung Association of Saskatchewan, Chinese Committee of Health and Family Planning Provincial Ministry of Health: Sasktchewan Other government body or committee: Saskatoon Health Region, Regina-Qu'Appelle Health Region International NGO: ATS, CHEST, FIRS Volunteer/Board or Committee Member: Lung Health Institute of Canada</p>	April 2017

Name	CTS affiliation	Disclosure	Updated
O'Donnell, Denis	COPD	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: Member, Division of Respiriology Professor (Medicine, Biomedical & Molecular Sciences, Kinesiology & Health Studies) University: Queen's University Hospital: Kingston General Hospital Research Funding: Peer-reviewed grants: William Spear & Richard Start Funds, Queen's University Ontario Thoracic Society Grant-in-Aid Canadian Respiratory Research Network CIHR Research & Development Research Program Department of Medicine Research Award, Queen's University SEAMO Clinician Scientist Development Program</p> <p>Industry-sponsored contracts: Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline Consultant/Advisor: Industry advisory board member: Almirall, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer Honoraria: Speaker: Almirall, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer</p>	March 2017
Sin, Don	COPD	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</p> <p>Academic appointment(s)/employment: University: University of British Columbia Hospital: St. Paul's Hospital Research Funding: Peer-reviewed grants: CIHR, Genome Canada Industry-sponsored contracts: Merck, AstraZeneca, BI Consultant/Advisor: Industry advisory board member: Regneron, Sanofi, BI, Vitaeris, Naegis Pharmaceuticals, AstraZeneca, Novartis Honoraria: Speaker: AstraZeneca, BI CME/Course development: St. Paul's Hospital Continuing Medical Education, UBC Respiratory Update Volunteer/Board or Committee Member: Charitable Organization/Not for profit: CIHR</p>	